EPW
UTHR icon

Evolve Private Wealth’s United Therapeutics UTHR Stock Holding History

Evolve Private Wealth’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.9M Sell
12,735
-178
-1% -$100K 0.42% 36
2026
Q1 		$7.66M Sell
12,913
-1,107
-8% -$551K 0.41% 35
2025
Q4 		$6.83M Buy
+14,020
New +$6.53M 0.4% 38

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Evolve Private Wealth's UTHR Position: Q2 2026 in Review

Evolve Private Wealth reduced its United Therapeutics (UTHR) stake by 1.4% in Q2 2026, selling an estimated $100K and leaving 12,735 shares worth $6.9M. The position accounts for 0.42% of the portfolio, ranked #36.

Evolve Private Wealth first reported a position in UTHR in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.66M in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Evolve Private Wealth held 12,735 shares of United Therapeutics worth $6.9M as of Q2 2026.
  • Evolve Private Wealth sold 178 United Therapeutics shares in Q2 2026, an estimated $100K.
  • United Therapeutics made up 0.42% of Evolve Private Wealth's portfolio in Q2 2026, its #36 holding.
  • Evolve Private Wealth first reported a position in United Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Evolve Private Wealth's United Therapeutics position peaked at $7.66M in Q1 2026.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Evolve Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.